Drug Profile
hPV 19
Alternative Names: Affecizx™; Anti-VEGF mAb - Stainwei Biotech; hPV 19K; hPV19; SOLOT-EyeLatest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Stainwei Biotech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders; Solid tumours
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in China (Parenteral)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Eye-disorders in China (Ophthalmic)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Solid-tumours in China (Parenteral)